ArriVent BioPharma, Inc.
NASDAQ Global MarketTotal Valuation
ArriVent BioPharma, Inc. carries a market capitalization of 1.44B, placing it among publicly traded companies globally. Its enterprise value stands at 719.32M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.44B |
| Enterprise Value | 719.32M |
Share Statistics
ArriVent BioPharma, Inc. currently has 45.31M shares outstanding.
| Shares Outstanding | 45.31M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 3.23 |
| P/TBV Ratio | 3.23 |
| P/FCF Ratio | -6.98 |
| P/OCF Ratio | -6.98 |
Financial Position
ArriVent BioPharma, Inc. maintains a current ratio of 13.95, meaning it holds 13.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 13.95 |
| Quick Ratio | 13.06 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | 0.00 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -55.17 |
| Return on Assets (ROA) | -51.43 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
ArriVent BioPharma, Inc.'s stock has gained approximately 53.29371% over the past 52 weeks. The 50-day moving average sits at 31.39, while the 200-day moving average is 26.67.
| Beta (5Y) | N/A |
| 52-Week Price Change | 53.29371% |
| 50-Day Moving Average | 31.39 |
| 200-Day Moving Average | 26.67 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -156.87M, while operating income came in at -156.87M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -156.87M |
| Pretax Income | -145.24M |
| Net Income | -145.24M |
| EBITDA | -156.87M |
| EBIT | -156.87M |
| Earnings Per Share (EPS) | -3.57 |
Balance Sheet
ArriVent BioPharma, Inc. holds 326.38M in cash and equivalents against 419,000.00 in total debt, resulting in a net debt position of -62.10M. Total book value stands at 323.98M, with working capital of 323.71M providing operational flexibility.
| Cash & Cash Equivalents | 326.38M |
| Total Debt | 419,000.00 |
| Net Debt | -62.10M |
| Equity (Book Value) | 323.98M |
| Book Value Per Share | 7.15 |
| Working Capital | 323.71M |
Cash Flow
ArriVent BioPharma, Inc. produced -134.47M in operating cash flow over the past twelve months.
| Operating Cash Flow | -134.47M |
| Capital Expenditures | N/A |
| Free Cash Flow | -134.47M |
| FCF Per Share | -3.31 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -24.03 |
| FCF Yield | -14.33 |
Scores
ArriVent BioPharma, Inc. posts an Altman Z-Score of 22.61, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 22.61 |